title: Monitoring anticoagulant therapy with new oral agents.
abstract: Thromboembolic disease is a major leading cause of mortality and morbidity in industrialized countries. Currently, the management of these patients is challenging due to the availability of new drugs with proven efficacy and security compared to traditional oral vitamin K antagonists. These compounds are characterized by a predictable pharmacokinetic profile for which blood monitoring is not routinely needed. Nevertheless, some data have suggested inter-patient variability in the anticoagulant effect of these drugs, raising concerns about their effectiveness and safety. Although mass-spectrometry is the gold standard to determine drug plasma concentrations, this method is not widely available in every-day practice and some coagulation assays are commonly used to determine the anticoagulant effect of these drugs. The present review aims to summarize the current knowledge regarding the clinical question of how and when to monitor patients with new anticoagulant oral agents.
authors.affiliation: Allan Ramos-Esquivel, Department of Pharmacology, School of Medicine, University of Costa Rica, San José 11501-2060, Costa Rica.
authors.forename: Allan
authors.initials: A
authors.lastname: Ramos-Esquivel
keywords: Anticoagulant agents; Apixaban; Dabigatran; Drug monitoring; Rivaroxaban